BioCentury
ARTICLE | Clinical News

RG-101: Additional Phase II data

July 18, 2016 7:00 AM UTC

Data from 78 evaluable treatment-naive patients with chronic HCV genotype 1 or 4 infection in an open-label, European Phase II trial showed that a single subcutaneous injection of 2 mg/kg RG-101 follo...